The latest research study “Herpes Simplex Virus Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global herpes simplex virus treatment market reached a value of US$ 2.32 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.25 Billion by 2027 exhibiting a CAGR of 5.50% during 2022-2027.
Covid-19 Impact:
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Industry Definition and Application:
Herpes simplex virus (HSV) represents a contagious infection that can spread via semen, saliva, and vaginal secretions and cause painful blisters or ulcers. It is usually diagnosed by physical examinations, fluid sampling, blood tests, etc. Presently, antiviral medications, such as acyclovir, famciclovir, valacyclovir, etc., are the most effective treatment options available for patients. These medications are administered through oral or intravenous (IV) routes to help reduce the frequency and severity of outbreaks, relieve symptoms, prevent the transmission of the virus, etc.
Global Herpes Simplex Virus Treatment Market Trends and Drivers:
The rising prevalence of hospital-acquired infections and low immunity disorders, on account of the sudden outbreak of the COVID-19 pandemic across the globe, is primarily driving the herpes simplex virus treatment market. Additionally, HSV increases the risk of transmitting and acquiring human immunodeficiency virus (HIV) disease and can lead to severe complications, including keratitis and encephalitis in individuals with long-term or chronic illnesses, which is further catalyzing the market growth. Besides this, the growing birth rates across developing countries are acting as significant growth-inducing factors. Moreover, the inflating investments in R&D activities aimed at developing low concentration acyclovir medications to expand the treatment options for genital and orolabial herpes are also positively influencing the global market. Apart from this, the introduction of antiviral creams or ointments that can relieve itching, burning, and tingling sensations caused by HSV is anticipated to fuel the herpes simplex virus treatment market over the forecasted period.
Download free sample brochure: https://www.imarcgroup.com/herpes-simplex-virus-treatment-market/requestsample
| Herpes Simplex Virus Treatment Market Report Scope | |
| Report Coverage | Details |
| Market size value in 2021 | US$ 2.32 Billion |
| Market forecast in 2027 | US$ 3.25 Billion |
| Growth Rate | CAGR of 5.50% from 2022 to 2027 |
| Base year for estimation | 2021 |
| Historical data | 2016-2021 |
| Forecast period | 2022-2027 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | Type, Drug Type, Route of Administration, Distribution Channel and Region |
| Regional scope | North America, Europe, Asia-Pacific, Latin America, Middle East and Africa |
| Key companies profiled | Agenus Inc., Apotex Inc., Avet Pharmaceuticals Inc., Carlsbad Tech, EPI Health LLC, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd. and Viatris Inc. |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
| Customization preview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Report Segmentation:
The report has been segmented the market into following categories:
Breakup by Type:
- Herpes Simples Virus-1 Infection
- Herpes Simplex Virus-2 Infection
- Others
Breakup by Drug Type:
- Acyclovir
- Valacyclovir
- Famciclovir
- Others
Breakup by Route of Administration:
- Oral
- Injectable
- Topical
Breakup by Distribution Channel:
- Hospital Pharmacy
- Drug Stores
- Retail Stores
- Online Pharmacy
By Geography:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
List of Major Key Players:
The major players in the market are Agenus Inc., Apotex Inc., Avet Pharmaceuticals Inc., Carlsbad Tech, EPI Health LLC, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd. and Viatris Inc.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
